What Alan Rickman's Story Can Help Us Understand About Pancreatic Cancer

What is on the record

Alan Rickman died on 14 January 2016, aged 69. The Guardian's obituary, published that day, said he had died of cancer.

Days later, the Pancreatic Cancer Action Network issued a statement saying he had died from pancreatic cancer at 69, and used the occasion to call for more attention to the disease.

Rickman had kept his illness private while he was alive. That is the whole of the public record, and this page does not go past it. Nothing here describes his stage, his treatment, or his choices, because he did not describe them.

What his death did do was make a great many people look up a disease they had never thought about. That is worth doing properly.

Where the pancreas sits, and why it matters

The pancreas is a gland about six inches long, shaped like a thin pear lying on its side, tucked behind the stomach and in front of the spine.

That position is the first problem. NCI's clinical summary lists it plainly: the pancreas is obscured by other organs and is hard to see clearly on imaging.

The gland does two separate jobs. Exocrine cells make digestive juices. Endocrine cells, including islet cells, make hormones such as insulin. Cancers arising from each behave so differently that NCI writes about them in separate summaries. The exocrine type is far more common. Our overview of pancreatic cancer covers both.

Why it is so often found late

NCI gives three reasons, and they compound.

There are no noticeable signs or symptoms in the early stages. When signs do appear, they resemble other illnesses such as pancreatitis or an ulcer. And the gland is hard to image.

The result shows in the registry. SEER, the federal cancer surveillance program, reports that only 15% of pancreatic cancers are found while still confined to the pancreas. Fifty-one percent are found after spread to distant sites. Those shares come from cases diagnosed in 2016 through 2022.

When to get checked

NCI's symptom list for pancreatic cancer is short:

• Jaundice — yellowing of the skin and the whites of the eyes.
• Light-colored stools or dark urine.
• Pain in the upper or middle abdomen and back.
• Weight loss for no known reason.
• Loss of appetite.
• Fatigue.

Two of these deserve emphasis.

Painless jaundice in an adult is never normal and should be assessed within days, not weeks. It happens when a tumor in the head of the pancreas blocks the bile duct. It is also, in a grim irony, one of the few ways this cancer announces itself early enough for surgery.

The other is the combination of upper abdominal pain that goes through to the back, plus weight loss you did not intend. Either alone is common. Together they warrant an appointment.

New diabetes in an adult over 50 with no obvious cause, particularly alongside weight loss, is also worth raising. NCI lists a personal history of diabetes among the risk factors.

Risk factors, and their limits

NCI lists smoking, excess body weight, a personal history of diabetes or chronic pancreatitis, a family history of pancreatic cancer or pancreatitis, and several inherited conditions: Lynch syndrome, Peutz-Jeghers syndrome, hereditary breast and ovarian cancer syndrome, familial atypical multiple mole melanoma, and ataxia-telangiectasia.

NCI adds the caveat that matters after a public death like this one. Many people with risk factors never develop pancreatic cancer, and others with no known risk factors do.

There is no screening test for pancreatic cancer in people at average risk. People with a strong family history or a known inherited syndrome may be offered surveillance, and that is a decision made with a care team.

What treatment involves

Surgery is the only route to cure, and most people are not eligible for it.

NCI describes three operations. The Whipple procedure removes the head of the pancreas, the gallbladder, part of the stomach, part of the small intestine, and the bile duct, leaving enough pancreas to make digestive juices and insulin. A total pancreatectomy removes the whole gland and several neighboring organs. A distal pancreatectomy removes the body and tail.

NCI's clinical summary is direct about the limits: surgical removal is the mainstay of curative treatment and helps people with small, localized tumors, but people with unresectable, metastatic, or recurrent disease are unlikely to benefit from it. Even after complete removal of a small tumor with no spread beyond the pancreatic capsule, NCI cites a five-year survival rate of 18% to 24%.

Chemotherapy carries most of the load. Modified FOLFIRINOX — oxaliplatin, leucovorin, irinotecan, and fluorouracil — is used before surgery in borderline cases, and gemcitabine-based regimens are used in others.

Palliative care is not an afterthought here. NCI lists relieving bile duct blockage, relieving stomach outlet obstruction, pain control, and psychological care as measures that improve quality of life. It states plainly that these may not affect survival, and it names them anyway.

What the survival figures show

American Cancer Society projections for 2026 put new pancreatic cancer diagnoses in the United States at about 67,530, with about 52,740 deaths. The median age at diagnosis is 71.

For people diagnosed from 2016 through 2022, five-year relative survival is 43.6% for localized disease, 17.0% for regional, and 3.4% for distant. Across all stages it is 13.7%.

That last figure has more than quadrupled since the mid-1970s, when it was under 4%. It remains the lowest of any major cancer.

These are registry averages across tens of thousands of people. They describe a population and not any individual, and they lag current treatment by years. Our page on cancer statistics covers how to read them.

What to keep in perspective

Rickman was 69 and had a life largely lived in public, and none of that predicts anything for anyone else. Age, stage, tumor location, and general health all differ.

His decision to keep the diagnosis private was his own, and it is not a model or a criticism of anyone who chooses differently.

And the low survival figures on this page are not a forecast. They are what happened to a large group of people diagnosed years ago, most of them found after the cancer had already spread. A person diagnosed today, at a different stage, is not that group.

Sources

• The Guardian: Alan Rickman obituary
• Pancreatic Cancer Action Network statement on Alan Rickman
• NCI PDQ: Pancreatic Cancer Treatment (Health Professional Version)
• NCI PDQ: Pancreatic Cancer Treatment (Patient Version)
• NCI SEER Stat Facts: Pancreatic Cancer

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.